within Pharmacolibrary.Drugs.ATC.S;

model S01EA04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 4.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 0.15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0021000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 12.0,            
    Vdp             = 0.0076,
    k12             = 1.65,
    k21             = 1.65
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Clonidine is a centrally acting alpha-2 adrenergic agonist used primarily for the treatment of hypertension, but also for attention deficit hyperactivity disorder (ADHD), certain pain conditions, withdrawal syndromes, and in ophthalmic formulation (with ATC code S01EA04) for lowering intraocular pressure in glaucoma or ocular hypertension. It remains an approved and clinically used medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following oral administration in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Blackburn, L, et al., &amp; Anderson, BJ (2014). Intranasal clonidine pharmacokinetics. <i>Paediatric anaesthesia</i> 24(3) 340–342. DOI:<a href=\"https://doi.org/10.1111/pan.12297\">10.1111/pan.12297</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24467572/\">https://pubmed.ncbi.nlm.nih.gov/24467572</a></p></li><li><p>Lowenthal, DT, et al., &amp; MacGregor, TR (1988). Clinical pharmacokinetics of clonidine. <i>Clinical pharmacokinetics</i> 14(5) 287–310. DOI:<a href=\"https://doi.org/10.2165/00003088-198814050-00002\">10.2165/00003088-198814050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3293868/\">https://pubmed.ncbi.nlm.nih.gov/3293868</a></p></li><li><p>MacCarthy, EP, &amp; Bloomfield, SS (1983). Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. <i>Pharmacotherapy</i> 3(4) 193–219. DOI:<a href=\"https://doi.org/10.1002/j.1875-9114.1983.tb03252.x\">10.1002/j.1875-9114.1983.tb03252.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6310529/\">https://pubmed.ncbi.nlm.nih.gov/6310529</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EA04;
